title: A randomized clinical trial comparing the efficacy of ranitidine and famotidine on intragastric acidity in critically ill pediatric patients.
abstract: We examined the efficacy of intravenous ranitidine and famotidine on raising intragastric pH in each of 10 critically ill pediatric patients. The severity of illness was assessed by using the modified zinner index score. The study had 3 phases and each phase took 24 hours. Intragastric pH was measured by continuous pH monitoring digitrapper for 72 hours. In phase 1 and 3, the patients did not receive any H2 blockers. In phase 2, they were randomized to receive intravenous ranitidine or famotidine. The majority of cases had intragastric pH < 4 in day 1 (base line). Ranitidine and famotidine increased total time of intragastric pH > or = 4 from the base line during day 2, 38.2 +/- 16.9 per cent and 60.3 +/- 24.8 per cent respectively (P0.004), but there was no statistical difference between the 2 medications in both Zinner index score 1 and score greater than 1 group (P 0.08, 0.45). Three cases in the famotidine group had successful prophylaxis with total time pH > or = 4 more than 80 per cent. Famotidine appeared to have a trend toward increasing intragastric pH in critically ill pediatric patients.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: P
authors.initials: P
authors.lastname: Aanpreung
authors.forename: N
authors.initials: N
authors.lastname: Vanprapar
authors.forename: C
authors.initials: C
authors.lastname: Susiva
authors.forename: C
authors.initials: C
authors.lastname: Parkpreaw
authors.forename: C
authors.initials: C
authors.lastname: Boonyachart
mesh_terms: D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D016638:Critical Illness; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects*; D007223:Infant; D008297:Male; D011899:Ranitidine / Q000627:therapeutic use*; D012307:Risk Factors; D018709:Statistics, Nonparametric
chemical_list: D006635:Histamine H2 Antagonists; D015738:Famotidine; D011899:Ranitidine